Retsevmo Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Zoledronic Acid Oresund Pharma 5 mg/100 ml Norveġja - Norveġiż - Statens legemiddelverk

zoledronic acid oresund pharma 5 mg/100 ml

oresund pharma aps - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg/100 ml

Mounjaro Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

mounjaro

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, type 2 - legemidler som brukes i diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 og 5.

Emgality Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

emgality

eli lilly nederland b.v. - galcanezumab - migrene lidelser - analgesics, galcanezumab - emgality er indisert for profylakse av migrene hos voksne som har minst 4 migrene dager per måned.

Granupas (previously Para-aminosalicylic acid Lucane) Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

granupas (previously para-aminosalicylic acid lucane)

eurocept international b. v. - para-aminosalicylic syre - tuberkulose - antimykobakterielle - granupas angis for bruk som en del av en passende kombinasjon diett for multi-resistente tuberkulose i voksne og pediatriske pasienter fra 28 dager alder og eldre når en effektiv behandling diett kan ellers ikke består av motstand eller toleranse (se seksjon 4. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Verzenios Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Aclasta Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

aclasta

sandoz pharmaceuticals d.d. - zoledronsyre - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - legemidler til behandling av bein sykdommer - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. behandling av osteoporose forbundet med langvarig systemisk glukokortikoid terapi i innlegget postmenopausale kvinner og hos menn med økt risiko for brudd. behandling av pagets sykdom i beinet.

Kepivance Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

kepivance

swedish orphan biovitrum ab (publ) - palifermin - mukositt - alle andre terapeutiske produkter - kepivance er angitt for å senke forekomsten, varighet og alvorlighetsgrad av muntlig mukositt hos voksne pasienter med hematologisk malignitet mottar myeloablative radiochemotherapy knyttet til en høy forekomst av alvorlig mukositt og krever autologous-haematopoietic-stilk-cellen støtte.

Vitaros 3 mg/ g Norveġja - Norveġiż - Statens legemiddelverk

vitaros 3 mg/ g

the simple pharma company limited - alprostadil - krem - 3 mg/ g

Memantine Merz Unjoni Ewropea - Norveġiż - EMA (European Medicines Agency)

memantine merz

merz pharmaceuticals gmbh   - memantinhydroklorid - alzheimers sykdom - andre anti-demens medisiner - behandling av pasienter med moderat til alvorlig alzheimers sykdom.